1. Drug Metabolism in Man (Enzymes in vitro) (1B1 - 1B24))

1B17 Inhibition of human steroid sulphotransferases by drugsimplications for adverse drug reactions.
Bamforth K.J. and M.W.H. Coughtrie
Dept. Biochemical Medicine, University of Dundee, Dundee DD1 9SY, Scotland.

1B2 Tolbutamide and phenytoin metabolism by human cytochromes P450.
Birkett D.J., P.I. Mackenzie, C.J. Doecke, M.E. McManus, J.O. Miners, R. Gasser, U. Meyer and M.E. Veronese
Dept. Clinical Pharmacology, Flinders Medical Centre, Bedford Park, SA 5042, Australia.

1B16 Human C-S lyase enzymes: transamination and structure-activity relationships.
Blagbrough J.S., L.D. Buckberry, B.W. Bycroft and P.N. Shaw
Dept. of Pharmaceutical Sciences, University of Nottingham, Nottingham NG7 2RD, UK.

1B14 Purification and characterisation of human hepatic C-S lyase.
Buckberry L.D., I.S. Blagbrough, B.W. Bycroft and P.N. Shaw
Dept. of Pharmaceutical Sciences, University of Nottingham, Nottingham, NG7 2RD, UK.

1B15 Human renal C-S lyases: two cytosolic isoenzymes.
Buckberry L.D., I.S. Blagbrough, B.W. Bycroft and **P.N. Shaw**
Dept. of Pharmaceutical Scienes, University of Nottingham, Nottingham NG7 2RD, UK.

1B3 Cytochrome P450IVA characterisation in human liver microsomes.
Chinje Edwin C.*, Alan Boobis^, Mike Tarbit° and G. Gordon Gibson*
* Molecular Toxicology Research Group, School of Biological Sciences, University of Surrey, Guildford, Surrey GU2 5XH, UK; ^ Royal Postgraduate Medical School, Clinical Pharmacology, London W2, UK; ° Glaxo Group Research, Dept. Biochemical Pharmacology, Ware, Herts., UK

1B4 Characterization of 3 human flavin containing monooxygenases.
Gasser Rodolfo, Ronald E. Tynes* and Urs A. Meyer
Dept. of Pharmacology, Biocenter of the University of Basel, CH-4056 Basel, Switzerland; * Biopharmaceutical Dept., Drug Safety, Sandoz Ltd., CH-4002 Basel, Switzerland.

1B1 Probing the active site of human cytochrome P450IID6 using 1,4-disubstituted piperazine and piperidine derivatives.
Hansen K.T., L. Koymans* and J.M. te Koppele*
Dept. of Drug Metabolism, CNS Division, Novo Nordisk A/S, DK-2880 Bagsværd, Denmark; * Dept. of Pharmacochemistry, Free University, De Boelelaan 1083, NL-1081 HV Amsterdam, The Netherlands.

1B19 Glucuronidation of 3'-azido-3'-deoxythymidine (AZT) in human liver microsomes: enzyme characterization and drug interferences.
Herber R., **J. Magdalou**, M. Haumont, G. Siest, R. Bidault^ and J.N. Colin^
Centre du Médicament, U.R.A CNRS n° 597, Faculté des Sciences Pharmaceutiques et Biologiques, 30, rue Lionnois, F-54000 Nancy, France;^ Laboratoires Wellcome, 159, rue Nationale, F-75013 Paris, France.

1B5 Role of P450 3A4 in 10,11-epoxidation of carbamazepine.
Kerr Bradley M., Susan M. Sanins, René H. Levy and **Kenneth E. Thummel**
Dept. of Pharmaceutics, University of Washington, Seattle, WA 98195, USA.

1B18 UDP-glucuronosyltransferase (UDPGT) activity toward digitoxigenin monodigitoxoside (DT1) in human liver microsomes.
Lacarelle B., J.F. Rajaonarison, M. Placidi, J. Catalin and R. Rahmani
Inserm U278, Faculté de Pharmacie, F-13385 Marseille Cedex 5, France.

1B21 Human liver microsomal glutathione transferase. Studies on the substrate specificity, activation by trypsin, isoelectric point, amino acid composition and primary sequence.
Mosaliou E., C. Andersson, G. Lundqvist, G. Andersson*, T. Bergman^, H. Jörnvall^ and R. Morgenstern
Dept. of Toxicology and^Dept. of Physiological Chemistry, Karolinska Institutet, Box 60400, S-10401 Stockholm, Sweden; * Dept. of Pathology, Karolinska Institutet, Huddinge Hospital, S-14186 Huddinge,Sweden

1B6 The role of cytochrome P450 IIIA in the metabolism of felodipine and aldrin by human liver microsomes.
Newlands A.J., M.D. Burke, D.A. Smith*, B.A. Jones* and G.M. Hawksworth
Clinical Pharmacology Unit, Dept. of Medicine and Therapeutics and Division of Pharmacology, School of Biomedical Sciences, University of Aberdeen, UK; * Pfizer Central Research, Sandwich, Kent, UK.

1B7 Different metabolic activities of expressed enzymes of two P-450IIC9 cDNA clones.
Ohgiya Satoru, Kozo Ishizaki, Nariko Shinriki and Tetsuya Kamataki*
Government Industrial Development Laboratory-Hokkaido, *Hokkaido University, Sapporo, Japan.

1B23 Conjugation pathways of human [illegible] on the interindividual variability.
Pacifici G.M., A. Temellini, A. Viani, P. Romiti, R. Bigotti, P. Donatelli, M. Castiglioni and L. Giuliani*
Depts. of Biomedicine and *Surgery, Medical School, University of Pisa, Pisa, Italy.

1B24 Sulphation and glucuronidation of ritodrine in fetal and adult human tissues.
Pacifici G.M., M. Kubrich, L. Giuliani^, M.H. de Vries** and A. Rane^^
Depts. of Experimental Biomedicine and ^ Surgery , Medical School, University of Pisa, Pisa, Italy; ** Duphar BV, Weesp, The Netherlands; ^^ Dept. of Clinical Pharmacology, Uppsala University Hospital, Uppsala, Sweden.

1B8 Coumarin 7-hydroxylation by human liver microsomes: pronounced inter-individual differences reflect differences in P-450 IIA3 levels.
Pearce R., M.P. Ariotto* and **A. Parkinson**
University of Kansas Medical Center, Kansas City, KS, USA and * Oxygene, Dallas, TX, USA.

1B22 Subcellular distribution of glutathione-related enzymes in human fetal adrenal gland.
Peng Ren-Xiu, Yu-Shan Wang and Shao-Bo Lai
Dept. of Pharmacology, Hubei Medical College, Wuhan, 430071, P.R. China.

1B12 Preparation of microsomes from human myometrium and uterine leiomyoma.
Pyykkö Kaija, Sirpa Lamminen*, Immo Rantala*, Michael Rorarius* and Risto Tuimala*
Dept. of Pharmacology, University of Turku, SF-20520 Turku, Finland; * Dept. of Clinical Sciences, University of Tampere, SF-33520 Tampere, Finland.

2028903427

Source: https://www.industrydocuments.ucsf.edu/docs/zhdl0000

1B20 Metabolism of zidovudine (AZT) by human liver microsomes: screening for inhibitors.
Rajaonarison J.-F., **B. Lacarelle**, G. de Sousa, M. Placidi, J. Catalin and R. Rahmani
INSERM U 278, Faculté de Pharmacie, F-13385 Marseille Cedex 5, France.

1B9 Cloning and expression of cDNAs for five members of the human cytochrome P4502C subfamily and correlation of 2C18 with (S)-mephenytoin hydroxylase phenotype.
Romkes M., M.B. Faletto, J.L. Raucy, J. Blaisdell, F.P. Guengerich, C.-H. Yun and **J.A. Goldstein**
NIEHS, Research Triangle Park, NC 27709, USA, University of New Mexico College of Pharmacy, Albuquerque, NM 87131, USA and Vanderbilt University School of Medicine, Nasville, TN 37232, USA.

1B10 Identification of the Cyt-P450 isoenzymes responsible for the metabolism of zolpidem.
Thénot Jean-Paul, Lydiane Pichard*, Gérard Gillet and Patrick Maurel*
Synthélabo-Recherche (L.E.R.S.), 23 av. Morane Saulnier, F-92360 Meudon-La-Fôret, France; * INSERM U-128 (CNRS), Route de Mende, Montpellier, France.

1B11 Involvement of the human hepatic cytochrome P-450 IIIA isozyme in the biotransformation of vindesine and vinblastine.
Zhou X.J., X.R. Pan-Zhou, T. Gauthier, B. Lacarelle, M. Placidi, J. Catalin and R. Rahmani
INSERM U 278, Faculté de Pharmacie, 27 bd. Jean Moulin, F-13385 Marseille Cedex 5, France.

1. Drug Metabolism in Man (Clinical Pharmacology (1C1 - 1C4))

1C2 Cimetidine/ascorbic acid and cytochrome P 450.
Boidin M.P. and A. Stuurman
Ignatius Ziekenhuis Breda, P.O. Box 90158, NL-4800 RK Breda, The Netherlands.

1C1 Cyclosporine in renal transplantation.
Islam S.I., Q.N. Masuda*, W. Adiku^, F. Shaheen^, N. Nezamuddin°, M. Hussein**, S.A. Wahab^^
King Abdul Aziz University, *Physical Pharmaceutist KAUH, ^Nephrologists KFH, °Urosurgeon KAAH, **Biostatistician PHC, ^^Clinical Pathologist NGH, P.O. Box 12653, Jeddah 21483, Saudi-Arabia.

1C3 Antileishmanial activities of some known and potential drugs on Leishmania Donovani Promastigotes.
Saha Ahindra K.
Dept. of Pharmaceutical Technology, Jadavpur University, Calcutta-700032, India.

2. Drug Metabolism in Animals in vivo: (Metabolic profiling (2A1 - 2A28))

2A26 Disposition of intravenous halofantrine (HAL) and its desbutyl metabolite (DES) in beagle dogs.
Ajayi F.O., N. Foster and L. Fleckenstein
Dept. of Pharmacology, WRAIR, Washington D.C., USA.

2A25 Metabolism and disposition of CPT-11, an antineoplastic agent, in rats.
Atsumi R., W. Suzuki, N. Yoshida and H. Hakusui
Research Institute, Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan.

2A1 A potentially new metabolic pathway: ethyl esterification of acitretin.
Chou R.C., R. Wyss, C.A. Huselton and U.W. Wiegand
F. Hoffmann-La Roche Ltd., Basel, Switzerland and Nutley, USA.

2A24 Study on the metabolism of a new antiarrhythmic agent (BGYKI-38 233) in rat.
Csárdi Anita, Gyula Horváth, Sándor Mészáros, Márta Pátfalusi and László Vereczkey
Institute of Drug Research, H-1325 Budapest, Hungary.

2A28 Effect of dose level and multiple dosing on the pharmacokinetics of idaverine in the dog.
De Lange N.
Duphar BV, P.O. Box 900, NL-1380 DA Weesp, The Netherlands.

2A22 The metabolism and disposition of eflumast (RP42068) in the rat.
Facchini V., G.D. Jones, **N.E. Wilsher** and P.P. Joannou
Biopharmacy R&D, Rhône-Poulenc Rorer Ltd., Dagenham Research Centre, Essex, UK.

2A21 Metabolic disposition of ebastine in rats.
Fujii T., T. Hatoyama, S. Matsumoto, H. Amejima, K. Yoshida, H. Miyazaki and M. Hasimoto
Research Laboratories, Dainippon Pharmaceutical Co., Ltd., Osaka, Japan.

2A2 *In vitro* and *in vivo* metabolism of Zolpidem in three animal species and in man.
Gillet Gérard, Jean-Paul Thénot and Paolo L. Morselli
Synthélabo-Recherche (L.E.R.S.), 23-25, avenue Morane Saulnier, F-92360 Meudon-La-Fôret, France.

2A20 Disposition of solanine in rats and in hamsters.
Groen Kees, Gerrit J.A. Speijers, Peter Besamusca, Diana P.K.H. Pereboom, Piet K. Beekhof and **Henk J.G.M. Derks**
Nat. Inst. of Public Health and Environmental Protection, P.O. Box 1, NL-3720 BA Bilthoven, The Netherlands.

2A19 Pharmacokinetics of licodaine and 2,6-xylidine in dogs.
Halldin Magnus M., É. Böö, P. Sheffels^, J.G. Slatter^ and T.A. Baillie^
Dept. of Drug Metabolism, Astra Pain Control AB, S 151 85 Södertälje, Sweden;^ Dept. of Medicinal Chemistry, University of Washington, Seattle, WA. 98195, USA.

2A18 Plasma levels of remoxipride over a 24-hour period following dietary administration in rat.
Hansson T., B. Bryske, É. Böö, S. Elofsson, E. Erixson-Carlqvist, I. Gagner Mälchert, U.-B. Gunnarsson, W. Hellström, I. Henriksson, K. Högberg and L.B. Nilsson
Astra Research Centre AB, S-151 85 Södertälje, Sweden.

2A17 Metabolism of 2-ethylhexanoic acid in the rat in vivo.
Hennigs Rolf, Roman Wodarz and **Albert W. Rettenmeier**
Dept. of Occupational and Social Medicine, University of Tübingen, FRG.

2A16 *In vivo* metabolism of cimetropium bromide.
Jahanshahi M., M. Kajbaf and J.W. Gorrod
Chelsea Department of Pharmacy, King's College, University of London, Manresa Road, London SW3 6LX, UK.

2A15 Metabolic studies with [125I]-defibrotide: methods for determination of the proportion of free iodide in biological samples.
Johnston A.M.*, C. Jones*, P.J. Mutch*, R. Pescador^ and G. Scott*
* Inveresk Research International, Tranent EH33 2NE, Scotland, UK;^ Crinos S.p.A., I-22079 Villa Guardia (Como), Italy.

2028903428

Source: https://www.industrydocuments.ucsf.edu/docs/zhdl0000